Fate Therapeutics
FATE
147 hedge funds and large institutions have $1.41B invested in Fate Therapeutics in 2019 Q4 according to their latest regulatory filings, with 34 funds opening new positions, 58 increasing their positions, 35 reducing their positions, and 30 closing their positions.
66% more repeat investments, than reductions
Existing positions increased: 58 | Existing positions reduced: 35
53% more call options, than puts
Call options by funds: $13.3M | Put options by funds: $8.71M
23% more capital invested
Capital invested by funds: $1.15B → $1.41B (+$268M)
17% more funds holding in top 10
Funds holding in top 10: 6 → 7 (+1)
13% more first-time investments, than exits
New positions opened: 34 | Existing positions closed: 30
1% less funds holding
Funds holding: 149 → 147 (-2)
2.46% less ownership
Funds ownership: 97.98% → 95.52% (-2.5%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Victory Capital Management
San Antonio,
Texas
|
+$9.08M |
| 2 |
BlackRock
New York
|
+$8.49M |
| 3 |
EC
EcoR1 Capital
San Francisco,
California
|
+$7.17M |
| 4 |
Ameriprise
Minneapolis,
Minnesota
|
+$7.11M |
| 5 |
Morgan Stanley
New York
|
+$6.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$28.3M |
| 2 |
PHS
PFM Health Sciences
San Francisco,
California
|
-$13.7M |
| 3 |
AVM
Arch Venture Management
Chicago,
Illinois
|
-$11.1M |
| 4 |
Franklin Resources
San Mateo,
California
|
-$8.81M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
-$6.31M |
FATE Hedge Fund Activity: Q4 2019 in Review
147 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in Fate Therapeutics (FATE) for Q4 2019, worth a combined $1.41B — up 23% from $1.15B a quarter earlier.
Buyers outnumbered sellers: 34 funds opened new FATE positions and 30 closed out — a net gain of 4 holders — while 58 added to existing stakes and 35 trimmed.
The largest buyer was Victory Capital Management, adding an estimated $9.08M. The largest seller was Millennium Management, cutting an estimated $28.3M.
- 147 institutional investors held Fate Therapeutics (FATE) as of Q4 2019, down from 149 in Q3 2019.
- Funds reported $1.41B of Fate Therapeutics stock for Q4 2019, up 23% quarter-over-quarter.
- 34 funds opened new Fate Therapeutics positions in Q4 2019 and 30 closed out, a net change of +4 holders.
- The largest Fate Therapeutics buyer in Q4 2019 was Victory Capital Management, an estimated $9.08M added.
- The largest Fate Therapeutics seller in Q4 2019 was Millennium Management, an estimated $28.3M sold.
Based on aggregated 13F filings for Q4 2019.